|
|
Transcripts that showed significantly decreased expression in daf-16(mgDf50) comparing to in N2 at L1 larva stage. |
DESeq v1.20.0 was used to analyze differential gene expression. Transcripts with adjusted p-value < 0.05 were considered differentialled expressed. |
WBPaper00048971:daf-16(mgDf50)_downregulated_L1
|
|
|
Transcripts that showed significantly decreased expression in eat-2(ad1116) comparing to in N2 at 3-days post L4 adult hermaphrodite animals. |
DESeq2(v1.14.1), fold change > 2, p-value < 0.05 |
WBPaper00055354:eat-2(ad1116)_downregulated
|
|
|
Transcripts that showed significantly increased expression in elli-1(sam-3) comparing to in N2 animals, accordingto tiling array analysis. |
Fold change > 1.2, q-value < 0.05. |
WBPaper00050743:elli-1(sam-3)_upregulated
|
|
|
Transcripts that showed significantly decreased expression after animals were treated with 100uM Rapamycin, 50uM Rifampicin and 100uM Psora from day 1 to day 3 adult hermaphradite. |
DESeq2(v1.14.1), fold change > 2, p-value < 0.05 |
WBPaper00055354:Rapamycin-Rifampicin-Psora_downregulated
|
|
|
Transcripts of noncoding genes that showed significantly increased expression in muscle. |
DESeq2 (version 1.24.0). Transcripts with a false-discovery rate adjusted p-value less than 0.05 were considered significantly differentially expressed. |
WBPaper00062325:muscle_enriched_noncoding-RNA
|
|
|
Transcripts that showed significantly decreased expression after animals were exposed to 500 uM of 3-dihydro-2-phenyl-sulfanylenebenzo[d] [1,3,2]-oxazaphosphole (FW1256) from L1 stage larvae onwards. |
The DESeq2 package (v1.24.0) was used to identify differentially expressed genes (DEGs). Fold change > 2, FDR < 0.05. |
WBPaper00061040:FW1256_downregulated
|
